ArticleMolecular pharmaceutics2014
Amphiphilic nanoparticles repress macrophage atherogenesis: novel core/shell designs for scavenger receptor targeting and down-regulation.
Article in Molecular pharmaceutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 34 citations in OpenAlex.
- Monocytes as a convergent nanoparticle therapeutic target for cardiovascular diseases.Advanced drug delivery reviews · 2022Pooled it
- Graphene Nanoplatelets Suppress Foam Cell Formation and Atherogenic Inflammation in Macrophages.Cellular and molecular bioengineering · 2026Article
- The Functional Role of Lipoproteins in Atherosclerosis: Novel Directions for Diagnosis and Targeting Therapy.Aging and disease · 2022Review
- Nanotechnological approach to delivering nutraceuticals as promising drug candidates for the treatment of atherosclerosis.Drug delivery · 2021Review
- Low-density lipoprotein nanomedicines: mechanisms of targeting, biology, and theranostic potential.Drug delivery · 2021Review
- The Opportunities and Challenges of Silica Nanomaterial for Atherosclerosis.International journal of nanomedicine · 2021Review
- Macrophage imaging and subset analysis using single-cell RNA sequencing.Nanotheranostics · 2021Article
- The Multifaceted Uses and Therapeutic Advantages of Nanoparticles for Atherosclerosis Research.Materials (Basel, Switzerland) · 2018Review
- Nanotherapeutics Containing Lithocholic Acid-Based Amphiphilic Scorpion-Like Macromolecules Reduce In Vitro Inflammation in Macrophages: Implications for Atherosclerosis.Nanomaterials (Basel, Switzerland) · 2018Article
- Computational Analysis on Down-Regulated Images of Macrophage Scavenger Receptor.Pharmaceutical research · 2017Article
- Athero-inflammatory nanotherapeutics: Ferulic acid-based poly(anhydride-ester) nanoparticles attenuate foam cell formation by regulating macrophage lipogenesis and reactive oxygen species generation.Acta biomaterialia · 2017Article
- Nanomedicines for dysfunctional macrophage-associated diseases.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Vascular-targeted nanocarriers: design considerations and strategies for successful treatment of atherosclerosis and other vascular diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2016Review
- Amphiphilic macromolecule nanoassemblies suppress smooth muscle cell proliferation and platelet adhesion.Biomaterials · 2016Article
- Nanotherapeutics for inhibition of atherogenesis and modulation of inflammation in atherosclerotic plaques.Cardiovascular research · 2016Article
- Designing polymers with sugar-based advantages for bioactive delivery applications.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- Sugar-based amphiphilic nanoparticles arrest atherosclerosis in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Osteogenic monocytes within the coronary circulation and their association with plaque vulnerability in patients with early atherosclerosis.International journal of cardiology · 2015Article
- Impact of Silver and Iron Nanoparticle Exposure on Cholesterol Uptake by Macrophages.Journal of nanomaterials · 2015Article
- MicroRNA-590 Inhibits Lipoprotein Lipase Expression and Prevents Atherosclerosis in apoE Knockout Mice.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Atherosclerosis, an inflammatory lipid-rich plaque disease is perpetuated by the unregulated scavenger-receptor-mediated uptake of oxidized lipoproteins (oxLDL) in macrophages. Current treatments lack the ability to directly inhibit oxLDL accumulation and foam cell conversion within diseased arteries. In this work, we harness nanotechnology to design and fabricate a new class of nanoparticles (NPs) based on hydrophobic mucic acid cores and amphiphilic shells with the ability to inhibit the uncontrolled uptake of modified lipids in human macrophages. Our results indicate that tailored NP core and shell formulations repress oxLDL internalization via dual complementary mechanisms. Specifically, the most atheroprotective molecules in the NP cores competitively reduced NP-mediated uptake to scavenger receptor A (SRA) and also down-regulated the surface expression of SRA and CD36. Thus, nanoparticles can be designed to switch activated, lipid-scavenging macrophages to antiatherogenic phenotypes, which could be the basis for future antiatherosclerotic therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.